Similar articles

• Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

  Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Rosenberg RD, et al. J Clin Invest. 1997 May 1;99(9):2062-70. doi: 10.1172/JCI119377. J Clin Invest. 1997. PMID: 9151776 Free PMC article. Review. No abstract available.
• Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains.

  Graham LD, Whitelock JM, Underwood PA. Graham LD, et al. Biochem Biophys Res Commun. 1999 Mar 24;256(3):542-8. doi: 10.1006/bbrc.1999.0377. Biochem Biophys Res Commun. 1999. PMID: 10080934
• Structural and functional diversity of the heparan sulfate proteoglycans.

  David G. David G. Adv Exp Med Biol. 1992;313:69-78. doi: 10.1007/978-1-4899-2444-5_7. Adv Exp Med Biol. 1992. PMID: 1442271 Review. No abstract available.
• Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells.

  Luo J, Kato M, Wang H, Bernfield M, Bischoff J. Luo J, et al. J Cell Biochem. 2001;80(4):522-31. J Cell Biochem. 2001. PMID: 11169736
• Release of endothelium-associated proteins into blood by injection of heparin in normal subjects and in patients with Type 1 diabetes.

  Myrup B, Yokoyama H, Kristiansen OP, Østergaard PB, Olivecrona T. Myrup B, et al. Diabet Med. 2004 Oct;21(10):1135-40. doi: 10.1111/j.1464-5491.2004.01313.x. Diabet Med. 2004. PMID: 15384962